



**Metrion Biosciences**, a specialist **ion channel drug discovery service provider**, is a Collaboration Partner of **Nanion Technologies** and offers assays on the **Patchliner** and **CardioExcyte 96** platforms



### Patchliner




- Fully automated planar patch clamp platform
- Recording from up to 8 cells simultaneously
- Gigaseal quality electrophysiology data
- Voltage- and ligand-gated ion channel assays

Metrion  
Biosciences



*Metrion Biosciences has been utilizing multiple Nanion Patchliner platforms since 2007 for:*

- Running high quality **ion channel drug discovery** and **cardiac safety assays**
- Running primary **ion channel target**, **gene family selectivity** and **MoA assays**
- Developing and running **screening assays** for **CRO** and **pharma** partners for both **voltage-** and **ligand-gated ion channel targets**



*Using the Patchliner, Metrion Biosciences has supported a major collaboration with a large EU pharmaceutical company since 2010.*

*Metrion routinely helps to bring a lead compound and a back-up series through to successful pre-clinical development.*



**Metrion Biosciences**, a specialist **ion channel drug discovery service provider**, is a Collaboration Partner of **Nanon Technologies** and offers assays on the **Patchliner** and **CardioExcyte 96** platforms



### CardioExcyte 96



- Fully automated hybrid EFP/impedance system
- Records the contractility and electrophysiology of intact ESC and iPSC cardiomyocyte networks
- Records from 96 wells simultaneously over minutes-to-days
- Non-invasive and label free measurements
- Part of CiPA cardiotoxicity validation studies

Nanon Technologies



**Metrion Biosciences** was one of the first CROs to validate the **CardioExcyte 96** platform for cardiac safety assays. Services offered now include:

- CiPA-compliant human iPSC cardiomyocyte safety studies
- Validation of human iPSC-derived cardiomyocyte cell lines
- Chronic cardiotoxicity assays (e.g. immuno-oncology)
- Acute and chronic cell cytotoxicity studies

